On Thursday, Boeing Co (NYSE:BA)’s shares declined -1.81% to $141.20.
The biennial Paris Air Show officially begins on Monday, June 15, but the two big commercial jet builders have already begun ratcheting up the public relations portion of the show. Given the boom in orders over the past several years, and the relatively low number of new orders so far this year, both Boeing Co. ( BA) and Airbus may have to focus on something besides large new orders for commercial planes.
Earlier this week, Airbus announced that it had received a firm order for 10 A321 and two A320 single-aisle planes from U.S. ultra-low-cost carrier Frontier Airlines. Neither part of the order includes the new engine option that Airbus is pushing. That is likely due to Frontier’s desire to remain an ultra-low-cost carrier and partly to fuel costs that are expected to remain low for several more years.
On Thursday morning, Boeing declared that a 787-9 that is being delivered to Vietnam Airlines will take part in a flying demonstration at the Paris show. The airline has ordered eight of the Boeing planes, and the plane that will fly in Paris is the first 787 to be delivered to the southeast Asian company.
The Boeing Company, together with its auxiliaries, designs, develops, manufactures, sells, services, and supports commercial jetliners, military aircraft, satellites, missile defense, human space flight, and launch systems and services worldwide. The company operates in five segments: Commercial Airplanes, Boeing Military Aircraft, Network & Space Systems, Global Services & Support, and Boeing Capital.
UnitedHealth Group Inc. (NYSE:UNH)’s shares dropped -1.44% to $116.65.
Advocate Health Care and UnitedHealth Group Inc. (UNH)are expanding their accountable care relationship to assist improve care coordination and enhance health services for more than 80,000 Illinois residents enrolled in United Healthcare’s employer-sponsored health plans, startning July 1, 2015.
Last year, Advocate Health Care and United Healthcare launched their accountable care relationship for more than 5,500 Illinois residents enrolled in UnitedHealthcare’s Medicare Advantage plans. Under this newly expanded relationship, physicians and hospitals associated with Advocate Health Care will be rewarded for achieving certain evidence-based measures for care offered to people enrolled in UnitedHealthcare employer-sponsored health plans.
UnitedHealthcare will complement Advocate Health Care’s clinical care and data by giving the group’s 5,500 physicians support needed to manage overall population health, counting technology and information that will assist them take specific actions that improve quality and lower costs. Actionable data can comprise patient profiles, specific Healthcare Effectiveness Data and Information Set (HEDIS) gaps, and real-time information about emergency room and inpatient admissions. Patient navigators may also support community-based care coordination, such as assisting with transition plans after an individual is discharged from the hospital, scheduling follow-up appointments and closing care gaps.
UnitedHealth Group Incorporated operates as a diversified health and well-being company in the United States. The company’s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; and health care coverage, and health and well-being services to individuals aged 50 and older addressing their needs for preventive and acute health care services. It also provides services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, Children’s Health Insurance Program, and health care programs; and health services, counting commercial health and dental benefits.
At the end of Thursday’s trade, NXP Semiconductors NV (NASDAQ:NXPI)‘s shares dipped -1.38% to $106.74.
NXP Semiconductors NV (NXPI) and Freescale Semiconductors, Ltd. (FSL) will each hold shareholder meetings on July 2, 2015 to vote on NXP’s acquisition of Freescale. The United States Securities and Exchange Commission has declared effective the registration statement on Form F-4 filed by NXP. NXP and Freescale have finalized the joint proxy statement/prospectus and expect to promptly start delivery to shareholders. The NXP and Freescale boards of directors recommend shareholders vote in favor of the merger.
NXP also declared that it received a request for additional information and documentary materials from the United States Federal Trade Commission (“FTC”) in connection with NXP’s pending merger with Freescale. The request was issued under notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”).
NXP Semiconductors N.V., a semiconductor company, provides high performance mixed signal and standard product solutions for radio frequency (RF), analog, power administration, interface, security, and digital processing products worldwide. It provides in-vehicle networking, car passive keyless entry and immobilization, and car radio and audio amplifiers; car solid state lighting drivers; communication products that are related to assisted and autonomous driving; ICs for e-government, transportation, and access administration; RF power amplifiers, small signal RF discretes, and RF ICs for mobile, consumer electronics, and cable television infrastructure; AC-DC power conversion ICs for notebook personal computers; low power audio ICs; and microcontrollers.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), ended its Thursday’s trading session with -0.95% loss, and closed at $8.84.
Ariad Pharmaceuticals, Inc. (ARIA) declared updated clinical data on its investigational tyrosine kinase inhibitor (TKI), brigatinib (AP26113), in patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. The current results comprise more mature efficacy data for brigatinib, counting updated response rates and median duration of response in ALK+ NSCLC patients, in addition to more extensive safety data for all patients in the trial.
The updated Phase 1/2 results were presented this morning at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
